SK biopharmaceuticals Co., Ltd.
Financials
Valuation Metrics
SK biopharmaceuticals Co., Ltd.'s Market Cap is ₩5.4T. At end of 2025 it was ₩9.8T. Ranked #94 of 2,414 in KR market (top 4%), #88 of 781 on KOSPI (top 11%), #6 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 3%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 5.42T KRW | KR#94/2,414 Sec#6/231 |
| Revenue | 861.34B KRW | KR#444/2,414 Sec#17/231 |
| Net Income | 391.91B KRW | KR#100/2,414 Sec#3/231 |
| Total Assets | 1.20T KRW | KR#432/2,414 Sec#22/231 |
| Net Assets | 826.27B KRW | KR#337/2,414 Sec#20/231 |
| Employees | 265 | KR#889/2,414 Sec#74/231 |
| Value | ||
| P/E | 13.83x | KR#1,041/2,414 Sec#63/231 |
| P/B | 6.56x | KR#2,309/2,414 Sec#202/231 |
| PEG | 0.14x | KR#502/2,414 Sec#28/231 |
| P/S | 6.29x | KR#2,206/2,414 Sec#149/231 |
| EV/EBITDA | 16.86x | KR#952/2,414 Sec#58/231 |
| FCF Yield | 3.13% | KR#991/2,414 Sec#61/231 |
| Profitability | ||
| ROE | 47.43% | KR#14/2,414 Sec#1/231 |
| ROA | 32.70% | KR#12/2,414 Sec#2/231 |
| Op. Margin | 35.20% | KR#36/2,414 Sec#9/231 |
| Revenue Growth | 38.86% | KR#290/2,414 Sec#33/231 |
| Earnings Growth | 97.64% | KR#400/2,414 Sec#27/231 |
| Financial Health | ||
| Debt Ratio | 45.03% | KR#892/2,414 Sec#102/231 |
| Total Debt | 0 KRW | KR—/2,414 Sec—/231 |
| FCF | 169.44B KRW | KR#127/2,414 Sec#4/231 |
| Cash | 307.77B KRW | KR#191/2,414 Sec#3/231 |
| Current Ratio | 2.72x | KR#627/2,414 Sec#83/231 |
| Net Debt/EBITDA | -1.01x | KR#378/2,414 Sec#20/231 |
| Performance | ||
| 1Y Return | -31.82% | KR#1,528/2,414 Sec#125/231 |
| 1M Return | -11.17% | KR#1,666/2,414 Sec#166/231 |
| From 52W High | -51.98% | KR#1,323/2,414 Sec#105/231 |
| 1Y MDD | -50.82% | KR#1,013/2,414 Sec#82/231 |
| Trading | ||
| Volume | 123,244 shares | KR#825/2,414 Sec#81/231 |
| Trading Value | 8.46B KRW | KR#284/2,414 Sec#21/231 |
| Foreign Own. | 12.16% | KR#408/2,414 Sec#32/231 |
| Per Share | ||
| EPS | 5,004 KRW | KR#212/2,414 Sec#11/231 |
| BPS | 10,551 KRW | KR#957/2,414 Sec#63/231 |
Company Info
SK Biopharm was newly established in 2011 through a spin-off of SK Co., Ltd.'s Life Science business division, having initiated new drug research and development in 1993. It launched cenobamate and solriamfetol, treatments for central nervous system epilepsy and sleep disorders, following U.S. FDA approval, and has signed technology export contracts with 17 countries. The company is expanding its CNS capabilities into oncology using RPT and TPD technologies and pursues new drug development through an AI drug design platform and a partnership with LifeSci Venture Partners. SK Biopharm is headquartered in Seongnam-si, Gyeonggi-do.